https://www.selleckchem.com/pr....oducts/eeyarestatin-
73; P less then 0.00001), respectively. For the subgroups PD-L1 expression (negative and high), there were benefits both observed in the PFS and OS in two sub-groups with atezolizumab (P 0.05). However, in the low expression of PD-L1 group, the subjects who received atezolizumab achieved PFS (OR 0.70; 95% CI 0.58-0.84, P=0.0002) advantage but OS advantage (OR 0.91; 95% CI 0.62-1.33, P=0.62). Conclusion In low expression of PD-L1 subgroups, a benefit was observed for PFS but OS. However, the status of PD-L1 expression cannot be re
Like
Comment
Share
